Novartis AG Common Stock (NY:NVS)

140.12 -0.88 (-0.62%)

Delayed Quote Updated: 9:49 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

59 60 Next >

Looking At Novartis's Recent Unusual Options Activity ↗

April 11, 2024

Via Benzinga

Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗

April 11, 2024

Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.

Via Investor's Business Daily

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

April 11, 2024

From Arvinas Inc.

Via GlobeNewswire

Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday? ↗

April 10, 2024

Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities.

Via Benzinga

Novartis AG (NYSE: NVS) Highlighted for Surprising Price Action

April 04, 2024

Via Investor Brand Network

1 Magnificent Dividend Stock to Buy and Hold ↗

March 24, 2024

The company's business went through some important changes last year.

Via The Motley Fool

2 Dividend Stocks to Buy and Hold Forever ↗

February 29, 2024

These businesses look too strong to fail.

Via The Motley Fool

SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today ↗

April 10, 2024

SoundHound AI stock is falling on Wednesday as investors in SOUN are worried about the company's plans for a secondary offering.

Via InvestorPlace

Topics Artificial Intelligence

Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost ↗

April 10, 2024

Alibaba stock is up on Wednesday as investors in BABA react to positive comments from cofounder Jack Ma concerning its leadership team.

Via InvestorPlace

Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts ↗

April 10, 2024

Novartis layoffs will see the healthcare company cut 680 jobs in the U.S. and Switzerland over the next two to three years.

Via InvestorPlace

Topics Workforce

Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says ↗

April 09, 2024

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho...

Via Benzinga

Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report ↗

April 09, 2024

Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools.

Via Benzinga

Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population ↗

April 08, 2024

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration...

Via Benzinga

Why Is Novartis Stock Trading Higher On Thursday? ↗

April 04, 2024

Novartis to file Pluvicto pre-taxane label expansion in 2H 2024 based on Phase 3 PSMAfore study data. Updated overall survival results show HR<1.0 in ITT population. rPFS consistent. Safety profile...

Via Benzinga

Harnessing AI for Drug Discovery: Top 3 Stocks to Watch ↗

March 26, 2024

As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly.

Via InvestorPlace

Topics Artificial Intelligence

Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund ↗

March 25, 2024

Norway's sovereign wealth fund has just five equity investments that represent nearly 13% of its total equity allocation.

Via Benzinga

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗

March 23, 2024

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

Via Talk Markets

Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge ↗

March 22, 2024

Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60...

Via Benzinga

Topics Lawsuit

GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy ↗

March 20, 2024

Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual...

Via Benzinga

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗

March 19, 2024

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...

Via Benzinga

FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer ↗

March 15, 2024

FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with...

Via Benzinga

Biotech’s Role in Addressing the Pancreatic Cancer Emergency

March 14, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

Via FinancialNewsMedia

Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗

March 11, 2024

Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets.

Via Benzinga

3 Dividend Stocks to Buy Hand Over Fist in March ↗

March 10, 2024

Income investors might want to load up on these great dividend stocks.

Via The Motley Fool

FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer ↗

March 08, 2024

FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...

Via Benzinga

Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 ↗

March 07, 2024

Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...

Via Benzinga

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗

March 06, 2024

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...

Via Benzinga

Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic ↗

March 05, 2024

As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.

Via Benzinga

Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children ↗

March 04, 2024

Novartis' Zolgensma gene therapy for spinal muscular atrophy latest SMART Phase 3b study reveals safety, efficacy, and significant milestones achieved. $1.21 billion sales reported in FY2023.

Via Benzinga

3 Stocks Primed for Exponential Returns by 2034 ↗

March 01, 2024

As investors, It's always good to look at things long-term. Here are three stocks that are primed for exponential returns in ten years.

Via InvestorPlace

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.